Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer

NCT01630590 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

62

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Cabozantinib
DRUG: Androgen Ablation Therapy

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]
[object Object]